HCC

General Cancer

Bert H. O&rsquo;Neil, MD, recently shared his considerations for treatment when treating patients with gastrointestinal cancers. O&rsquo;Neil reviewed how he would treat patients with colon cancer and patients with hepatocellular carcinoma based on case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives presentation.<br /> &nbsp;

The combination of the VEGFR/FGFR inhibitor lenvatinib and the PD-1 inhibitor pembrolizumab induced a confirmed overall response rate of 26.9% (95% CI, 11.6%-47.8%) in patients with unresectable hepatocellular carcinoma, according to results from a 2-part, phase Ib trial.

In results from the phase III REACH-2 trial,&nbsp;ramucirumab reduced the risk of death by 29% versus placebo as a second-line treatment for&nbsp;patients with advanced hepatocellular carcinoma. Results from the study were presented during the&nbsp;2018 ASCO Annual Meeting.

The review period for lenvatinib as a first-line treatment for patients with unresectable hepatocellular carcinoma has been extended by the FDA. According to Eisai and Merck, the companies codeveloping the drug, this will allow ample time to review the application.&nbsp;

A supplemental new drug application seeking the approval of cabozantinib for the treatment of patients with previously-treated advanced hepatocellular carcinoma has been accepted by the FDA, according to a statement from Exelixis, the company developing the agent.

Laura Dawson, MD,&nbsp;discusses the current and future role of SBRT in the treatment of liver tumors.

According to additional analyses from the phase III RESORCE trial published in the<em> Journal of Hepatology,&nbsp;s</em>econd-line regorafenib continued to show antitumor activity regardless of prior dose or time to progression on frontline sorafenib (Nexavar) for patients with unresectable advanced hepatocellular carcinoma.